Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prazosin in Adults With Anxiety Disorders
NCT03894345Phase 1Suspended
- Sponsor
- University of Manitoba
- Start
- May 2019
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of prazosin in anxiety disorder, sponsored by University of Manitoba. Primary endpoint: Change in Anxiety Symptoms at 8 weeks. Started May 2019; status: suspended.
02
Drugs
prazosin
03
Conditions
anxiety disorder
Beyond the preview
Go deeper on NCT03894345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03894345.